期刊文献+

左炔诺孕酮宫内缓释系统与长效醋酸甲羟孕酮治疗子宫内膜异位症的临床疗效 被引量:6

Clinical efficacies of levonorgestrel-releasing intrauterine system and depot medroxyprogesterone acetate for treatment of endometriosis
原文传递
导出
摘要 目的:比较左炔诺孕酮宫内缓释系统(LNG-IUS)与长效醋酸甲羟孕酮(Depot-MPA)治疗子宫内膜异位症的临床疗效。方法:保守性手术后即刻或单纯疼痛复发后患者87例,42例放置LNG-IUS,45例在3年内每隔3个月肌注长效醋酸甲羟孕酮(Depot-MPA)150 mg,比较临床症状控制情况、复发率、依从性、骨密度。结果:两种治疗方案均能控制临床疼痛症状及复发率。LNG-IUS治疗组患者依从性优于长效醋酸甲羟孕酮治疗组。LNG-IUS治疗组腰椎及股骨颈Wards三角区骨密度(BMD)变化幅度比长效醋酸甲羟孕酮治疗组大。结论:LNG-IUS治疗组可以有效地控制子宫内症膜异位症的临床症状和复发率,患者依从性好,骨密度可以得到改善,而长效醋酸甲羟孕酮治疗组出现骨密度下降。 Objective: To compare the clinical efficacies of levonorgestrel -releasing intrauterine system (LNG -IUS) and depot medroxyprogesterone acetate for treatment of endometriosis. Methods: Eighty - seven patients with immediate pain or recurrence of simple pain after conservative surgery were selected, 42 cases received LNG - IUS, and 45 cases were treated with intramuscular injection of depot medroxyprogesterone acetate (150 mg) every three months within three year; the controlling situations of clinical symptoms, recurrence rates, compliances, and bone mineral densities in the two groups were compared. Results: Both the two therapeutic schemes could control clinical symptoms and recurrence rate ; the compliance of patients in LNG - IUS group was better than that in depot medroxyprogesterone ace- tate group; the change amplitudes of bone mineral densities of lumbar vertebrae and Wards trigonum of collum femoris in LNG - IUS group were larger than those in depot medroxyprogesterone acetate group. Conclusion: LNG - IUS can effectively control clinical symptoms and re- currence rate of endometriosis, the compliance of patients is good, and bone mineral density is improved, while in depot medroxyprogesterone acetate group, bone mineral density decreases.
出处 《中国妇幼保健》 CAS 北大核心 2012年第35期5758-5761,共4页 Maternal and Child Health Care of China
关键词 骨密度 长效醋酸甲羟孕酮 子宫内膜异位症 左炔诺孕酮缓释系统 Bone mineral density Depot medroxyprogesterone acetate Endometriosis Levonorgestrel - releasing intrauterine system
  • 相关文献

参考文献10

  • 1Schlaff WD, Carson SA, Luciano A et al. Subcutaneous injec- tion of depot medroxyprogesterone acetate compared with leu- prolide acetate in the treatment of endometriosis - associated pain [J] . Fertil Steril, 2006, 85 (2): 314.
  • 2Telimaa S, Puolakka J, Ronnberg Iet al. Placebo - controlled comparison of danazol and high - dose medroxyprogesterone ac- etate in the treatment of endometriosis [J]. Gynecol Endocri- nol, 1987, 1:13.
  • 3Shaarawy MEI, Mallah SY, Seoudi S et al. Effects of the long - term use of depot medroxyprogesterone acetate as hor- monal contraceptive on bone mineral denisity and biochemical markers of bone remodeling [ J ] . Contracept, 2006, 74 (4): 297.
  • 4Kaunitz AM, Miller PD, Rice VM et al. Bone mineral density in women age 25 - 35 years receiving depot medroxyprogester- one acetate: recovery following discontinuation [J] . Contra- cept, 2006, 74 (2): 90.
  • 5Albertazzi P, Bottazzi M, Steel SA et al. Bone mineral density and depot medroxyprogesterone acetate [ J ] . Contracept, 2006, 73 (6): 577.
  • 6魏丽娜,祁秀娟,赵文翠,段玉英,吕映频.左炔诺孕酮宫内缓释系统治疗子宫腺肌病疗效观察[J].中国实用妇科与产科杂志,2007,23(3):192-194. 被引量:48
  • 7Vercellini P, Aimi G, Panazza Set al. A levonoregestrel - re- leasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study [ J]. Fertil Steril, 1999, 72 (3): 505.
  • 8Cho S, Nam A, Kim H et al. Clinical effects of the levonorg- estrel - releasing intrauterine device in patients with adenomyo- sis [J] . Am J Obetet Gynecol, 2008, 198 (4) : 373.
  • 9Osteen KG, Bruner- Tran KL, Ong D et al. Paracrine media- tors of endometrial matrix metalloproteinases expression: po- tential targets for progestin - based treatment of endometriosis [J] . Ann NY AcadSci, 2002, 955:139.
  • 10Bahamondes L, Espejo -Acre X, Hidalgo MM et al. A cross - sectional study of the forearm bone density of long - term users of levonorgestrel - releasing intrauterine system [ J] . Hum Reprod, 2006, 21 (5) : 1316.

二级参考文献7

  • 1任艳丽,胡生海,张海礁.祛瘀痛经汤治疗子宫内膜异位症痛经55例临床观察[J].江西中医药,2005,36(1):31-32. 被引量:12
  • 2杨幼林,郑淑蓉,李克敏,张炳兰.两种不同剂量米非司酮治疗子宫肌瘤的疗效观察[J].中华妇产科杂志,1996,31(10):624-626. 被引量:217
  • 3Higham JM, O' Brien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart [J]. Br J Obste Gynecol,1990,97 ( 7 ) :734-739.
  • 4Tang GW, Los S. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women : efficacy versus acceptability[J]. Contraception, 1995,51 (4) :231-235.
  • 5Gardner FJE, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomized controlled trial[ J ]. Lancet, 2000,356:1711-1717.
  • 6Jarvela I, Tekay A ,Jouppila P, The effect of a levonorgestrel intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women [ J ]. Hum Reprod, 1998,13:3379-3383.
  • 7Farhana BL,Joseph OE,Justin CK. The efficacy, side-eitects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen(levonorgestrel) : a 3-year follow-up [ J]. Hum Reprod, 2005,20( 3 ) :789-793.

共引文献47

同被引文献51

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部